| Objective To investigate the effect of alendronate on bone strength in postmenopausal osteoporosis (OP) patients with osteoarthritis (OA). Methods One hundred and forty-four patients diagnosed and treated in osteoporosis clinic of the Affiliated Hospital of North China University of Science and Technology from May 2016 to October 2019 were selected. They were divided into OP+OA group (73 cases) and OP group (71 cases) according to the diagnosis. The patients in the two groups received alendronate once a week for 12 months. The changes of CSA, CSMI, Z, CT, BR, BMD, VAS, Lysholm knee joint scores, and biochemical indexes were compared before and after the treatment. Results After the treatment, CSA, CSMI, Z, BMD of the lumbar vertebrae and femoral neck, and Lysholm knee joint scores in the two groups were higher than those before the treatment (P<0.05). BMD of the lumbar vertebrae and femoral neck in OP+OA group was higher than that in OP group after 12 months of the treatment (P<0.05). After the treatment, BR and VAS were lower than those before treatment in the two groups (P<0.05). BR and VAS in the OP+OA group were lower than those in the OP group after 12 months of the treatment (P<0.05). Conclusion Alendronate not only improves BMD and relieves joint symptoms, but also increases bone strength of the hip. |